Copyright Reports & Markets. All rights reserved.

Global Recombinant Antibodies (rAbs) Market Research Report 2021

Buy now

1 Recombinant Antibodies (rAbs) Market Overview

  • 1.1 Product Overview and Scope of Recombinant Antibodies (rAbs)
  • 1.2 Recombinant Antibodies (rAbs) Segment by Type
    • 1.2.1 Global Recombinant Antibodies (rAbs) Sales Growth Rate Comparison by Type (2021-2027)
    • 1.2.2 Rabbit
    • 1.2.3 Mouse
    • 1.2.4 Goat
    • 1.2.5 Others
  • 1.3 Recombinant Antibodies (rAbs) Segment by Application
    • 1.3.1 Global Recombinant Antibodies (rAbs) Sales Comparison by Application: (2021-2027)
    • 1.3.2 Hospitals & Diagnostic Laboratories
    • 1.3.3 Pharmaceutical & Biotechnology
    • 1.3.4 Research Institutes
    • 1.3.5 Others
  • 1.4 Global Recombinant Antibodies (rAbs) Market Size Estimates and Forecasts
    • 1.4.1 Global Recombinant Antibodies (rAbs) Revenue 2016-2027
    • 1.4.2 Global Recombinant Antibodies (rAbs) Sales 2016-2027
    • 1.4.3 Recombinant Antibodies (rAbs) Market Size by Region: 2016 Versus 2021 Versus 2027

2 Recombinant Antibodies (rAbs) Market Competition by Manufacturers

  • 2.1 Global Recombinant Antibodies (rAbs) Sales Market Share by Manufacturers (2016-2021)
  • 2.2 Global Recombinant Antibodies (rAbs) Revenue Market Share by Manufacturers (2016-2021)
  • 2.3 Global Recombinant Antibodies (rAbs) Average Price by Manufacturers (2016-2021)
  • 2.4 Manufacturers Recombinant Antibodies (rAbs) Manufacturing Sites, Area Served, Product Type
  • 2.5 Recombinant Antibodies (rAbs) Market Competitive Situation and Trends
    • 2.5.1 Recombinant Antibodies (rAbs) Market Concentration Rate
    • 2.5.2 The Global Top 5 and Top 10 Largest Recombinant Antibodies (rAbs) Players Market Share by Revenue
    • 2.5.3 Global Recombinant Antibodies (rAbs) Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
  • 2.6 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Recombinant Antibodies (rAbs) Retrospective Market Scenario by Region

  • 3.1 Global Recombinant Antibodies (rAbs) Retrospective Market Scenario in Sales by Region: 2016-2021
  • 3.2 Global Recombinant Antibodies (rAbs) Retrospective Market Scenario in Revenue by Region: 2016-2021
  • 3.3 North America Recombinant Antibodies (rAbs) Market Facts & Figures by Country
    • 3.3.1 North America Recombinant Antibodies (rAbs) Sales by Country
    • 3.3.2 North America Recombinant Antibodies (rAbs) Revenue by Country
    • 3.3.3 United States
    • 3.3.4 Canada
  • 3.4 Europe Recombinant Antibodies (rAbs) Market Facts & Figures by Country
    • 3.4.1 Europe Recombinant Antibodies (rAbs) Sales by Country
    • 3.4.2 Europe Recombinant Antibodies (rAbs) Revenue by Country
    • 3.4.3 Germany
    • 3.4.4 France
    • 3.4.5 U.K.
    • 3.4.6 Italy
    • 3.4.7 Russia
  • 3.5 Asia Pacific Recombinant Antibodies (rAbs) Market Facts & Figures by Region
    • 3.5.1 Asia Pacific Recombinant Antibodies (rAbs) Sales by Region
    • 3.5.2 Asia Pacific Recombinant Antibodies (rAbs) Revenue by Region
    • 3.5.3 China
    • 3.5.4 Japan
    • 3.5.5 South Korea
    • 3.5.6 India
    • 3.5.7 Australia
    • 3.5.8 Taiwan
    • 3.5.9 Indonesia
    • 3.5.10 Thailand
    • 3.5.11 Malaysia
  • 3.6 Latin America Recombinant Antibodies (rAbs) Market Facts & Figures by Country
    • 3.6.1 Latin America Recombinant Antibodies (rAbs) Sales by Country
    • 3.6.2 Latin America Recombinant Antibodies (rAbs) Revenue by Country
    • 3.6.3 Mexico
    • 3.6.4 Brazil
    • 3.6.5 Argentina
  • 3.7 Middle East and Africa Recombinant Antibodies (rAbs) Market Facts & Figures by Country
    • 3.7.1 Middle East and Africa Recombinant Antibodies (rAbs) Sales by Country
    • 3.7.2 Middle East and Africa Recombinant Antibodies (rAbs) Revenue by Country
    • 3.7.3 Turkey
    • 3.7.4 Saudi Arabia
    • 3.7.5 UAE

4 Global Recombinant Antibodies (rAbs) Historic Market Analysis by Type

  • 4.1 Global Recombinant Antibodies (rAbs) Sales Market Share by Type (2016-2021)
  • 4.2 Global Recombinant Antibodies (rAbs) Revenue Market Share by Type (2016-2021)
  • 4.3 Global Recombinant Antibodies (rAbs) Price by Type (2016-2021)

5 Global Recombinant Antibodies (rAbs) Historic Market Analysis by Application

  • 5.1 Global Recombinant Antibodies (rAbs) Sales Market Share by Application (2016-2021)
  • 5.2 Global Recombinant Antibodies (rAbs) Revenue Market Share by Application (2016-2021)
  • 5.3 Global Recombinant Antibodies (rAbs) Price by Application (2016-2021)

6 Key Companies Profiled

  • 6.1 Abcam
    • 6.1.1 Abcam Corporation Information
    • 6.1.2 Abcam Description and Business Overview
    • 6.1.3 Abcam Recombinant Antibodies (rAbs) Sales, Revenue and Gross Margin (2016-2021)
    • 6.1.4 Abcam Recombinant Antibodies (rAbs) Product Portfolio
    • 6.1.5 Abcam Recent Developments/Updates
  • 6.2 Abeomics
    • 6.2.1 Abeomics Corporation Information
    • 6.2.2 Abeomics Description and Business Overview
    • 6.2.3 Abeomics Recombinant Antibodies (rAbs) Sales, Revenue and Gross Margin (2016-2021)
    • 6.2.4 Abeomics Recombinant Antibodies (rAbs) Product Portfolio
    • 6.2.5 Abeomics Recent Developments/Updates
  • 6.3 Abnova Corporation
    • 6.3.1 Abnova Corporation Corporation Information
    • 6.3.2 Abnova Corporation Description and Business Overview
    • 6.3.3 Abnova Corporation Recombinant Antibodies (rAbs) Sales, Revenue and Gross Margin (2016-2021)
    • 6.3.4 Abnova Corporation Recombinant Antibodies (rAbs) Product Portfolio
    • 6.3.5 Abnova Corporation Recent Developments/Updates
  • 6.4 Absolute Antibody
    • 6.4.1 Absolute Antibody Corporation Information
    • 6.4.2 Absolute Antibody Description and Business Overview
    • 6.4.3 Absolute Antibody Recombinant Antibodies (rAbs) Sales, Revenue and Gross Margin (2016-2021)
    • 6.4.4 Absolute Antibody Recombinant Antibodies (rAbs) Product Portfolio
    • 6.4.5 Absolute Antibody Recent Developments/Updates
  • 6.5 Activity Signaling
    • 6.5.1 Activity Signaling Corporation Information
    • 6.5.2 Activity Signaling Description and Business Overview
    • 6.5.3 Activity Signaling Recombinant Antibodies (rAbs) Sales, Revenue and Gross Margin (2016-2021)
    • 6.5.4 Activity Signaling Recombinant Antibodies (rAbs) Product Portfolio
    • 6.5.5 Activity Signaling Recent Developments/Updates
  • 6.6 AIVD Biotech
    • 6.6.1 AIVD Biotech Corporation Information
    • 6.6.2 AIVD Biotech Description and Business Overview
    • 6.6.3 AIVD Biotech Recombinant Antibodies (rAbs) Sales, Revenue and Gross Margin (2016-2021)
    • 6.6.4 AIVD Biotech Recombinant Antibodies (rAbs) Product Portfolio
    • 6.6.5 AIVD Biotech Recent Developments/Updates
  • 6.7 Bio X Cell
    • 6.6.1 Bio X Cell Corporation Information
    • 6.6.2 Bio X Cell Description and Business Overview
    • 6.6.3 Bio X Cell Recombinant Antibodies (rAbs) Sales, Revenue and Gross Margin (2016-2021)
    • 6.4.4 Bio X Cell Recombinant Antibodies (rAbs) Product Portfolio
    • 6.7.5 Bio X Cell Recent Developments/Updates
  • 6.8 BioLegend
    • 6.8.1 BioLegend Corporation Information
    • 6.8.2 BioLegend Description and Business Overview
    • 6.8.3 BioLegend Recombinant Antibodies (rAbs) Sales, Revenue and Gross Margin (2016-2021)
    • 6.8.4 BioLegend Recombinant Antibodies (rAbs) Product Portfolio
    • 6.8.5 BioLegend Recent Developments/Updates
  • 6.9 Bio-Rad
    • 6.9.1 Bio-Rad Corporation Information
    • 6.9.2 Bio-Rad Description and Business Overview
    • 6.9.3 Bio-Rad Recombinant Antibodies (rAbs) Sales, Revenue and Gross Margin (2016-2021)
    • 6.9.4 Bio-Rad Recombinant Antibodies (rAbs) Product Portfolio
    • 6.9.5 Bio-Rad Recent Developments/Updates
  • 6.10 Bon Opus Biosciences
    • 6.10.1 Bon Opus Biosciences Corporation Information
    • 6.10.2 Bon Opus Biosciences Description and Business Overview
    • 6.10.3 Bon Opus Biosciences Recombinant Antibodies (rAbs) Sales, Revenue and Gross Margin (2016-2021)
    • 6.10.4 Bon Opus Biosciences Recombinant Antibodies (rAbs) Product Portfolio
    • 6.10.5 Bon Opus Biosciences Recent Developments/Updates
  • 6.11 Creative Biolabs
    • 6.11.1 Creative Biolabs Corporation Information
    • 6.11.2 Creative Biolabs Recombinant Antibodies (rAbs) Description and Business Overview
    • 6.11.3 Creative Biolabs Recombinant Antibodies (rAbs) Sales, Revenue and Gross Margin (2016-2021)
    • 6.11.4 Creative Biolabs Recombinant Antibodies (rAbs) Product Portfolio
    • 6.11.5 Creative Biolabs Recent Developments/Updates
  • 6.12 Creative Diagnostics
    • 6.12.1 Creative Diagnostics Corporation Information
    • 6.12.2 Creative Diagnostics Recombinant Antibodies (rAbs) Description and Business Overview
    • 6.12.3 Creative Diagnostics Recombinant Antibodies (rAbs) Sales, Revenue and Gross Margin (2016-2021)
    • 6.12.4 Creative Diagnostics Recombinant Antibodies (rAbs) Product Portfolio
    • 6.12.5 Creative Diagnostics Recent Developments/Updates
  • 6.13 Enzo Life Sciences, Inc.
    • 6.13.1 Enzo Life Sciences, Inc. Corporation Information
    • 6.13.2 Enzo Life Sciences, Inc. Recombinant Antibodies (rAbs) Description and Business Overview
    • 6.13.3 Enzo Life Sciences, Inc. Recombinant Antibodies (rAbs) Sales, Revenue and Gross Margin (2016-2021)
    • 6.13.4 Enzo Life Sciences, Inc. Recombinant Antibodies (rAbs) Product Portfolio
    • 6.13.5 Enzo Life Sciences, Inc. Recent Developments/Updates
  • 6.14 GRP GmbH
    • 6.14.1 GRP GmbH Corporation Information
    • 6.14.2 GRP GmbH Recombinant Antibodies (rAbs) Description and Business Overview
    • 6.14.3 GRP GmbH Recombinant Antibodies (rAbs) Sales, Revenue and Gross Margin (2016-2021)
    • 6.14.4 GRP GmbH Recombinant Antibodies (rAbs) Product Portfolio
    • 6.14.5 GRP GmbH Recent Developments/Updates
  • 6.15 HUABIO
    • 6.15.1 HUABIO Corporation Information
    • 6.15.2 HUABIO Recombinant Antibodies (rAbs) Description and Business Overview
    • 6.15.3 HUABIO Recombinant Antibodies (rAbs) Sales, Revenue and Gross Margin (2016-2021)
    • 6.15.4 HUABIO Recombinant Antibodies (rAbs) Product Portfolio
    • 6.15.5 HUABIO Recent Developments/Updates
  • 6.16 Miltenyi Biotec
    • 6.16.1 Miltenyi Biotec Corporation Information
    • 6.16.2 Miltenyi Biotec Recombinant Antibodies (rAbs) Description and Business Overview
    • 6.16.3 Miltenyi Biotec Recombinant Antibodies (rAbs) Sales, Revenue and Gross Margin (2016-2021)
    • 6.16.4 Miltenyi Biotec Recombinant Antibodies (rAbs) Product Portfolio
    • 6.16.5 Miltenyi Biotec Recent Developments/Updates
  • 6.17 NSJ Bioreagents
    • 6.17.1 NSJ Bioreagents Corporation Information
    • 6.17.2 NSJ Bioreagents Recombinant Antibodies (rAbs) Description and Business Overview
    • 6.17.3 NSJ Bioreagents Recombinant Antibodies (rAbs) Sales, Revenue and Gross Margin (2016-2021)
    • 6.17.4 NSJ Bioreagents Recombinant Antibodies (rAbs) Product Portfolio
    • 6.17.5 NSJ Bioreagents Recent Developments/Updates
  • 6.18 PROGEN
    • 6.18.1 PROGEN Corporation Information
    • 6.18.2 PROGEN Recombinant Antibodies (rAbs) Description and Business Overview
    • 6.18.3 PROGEN Recombinant Antibodies (rAbs) Sales, Revenue and Gross Margin (2016-2021)
    • 6.18.4 PROGEN Recombinant Antibodies (rAbs) Product Portfolio
    • 6.18.5 PROGEN Recent Developments/Updates
  • 6.19 RevMab Biosciences USA, Inc.
    • 6.19.1 RevMab Biosciences USA, Inc. Corporation Information
    • 6.19.2 RevMab Biosciences USA, Inc. Recombinant Antibodies (rAbs) Description and Business Overview
    • 6.19.3 RevMab Biosciences USA, Inc. Recombinant Antibodies (rAbs) Sales, Revenue and Gross Margin (2016-2021)
    • 6.19.4 RevMab Biosciences USA, Inc. Recombinant Antibodies (rAbs) Product Portfolio
    • 6.19.5 RevMab Biosciences USA, Inc. Recent Developments/Updates
  • 6.20 Signalway Antibody LLC
    • 6.20.1 Signalway Antibody LLC Corporation Information
    • 6.20.2 Signalway Antibody LLC Recombinant Antibodies (rAbs) Description and Business Overview
    • 6.20.3 Signalway Antibody LLC Recombinant Antibodies (rAbs) Sales, Revenue and Gross Margin (2016-2021)
    • 6.20.4 Signalway Antibody LLC Recombinant Antibodies (rAbs) Product Portfolio
    • 6.20.5 Signalway Antibody LLC Recent Developments/Updates

7 Recombinant Antibodies (rAbs) Manufacturing Cost Analysis

  • 7.1 Recombinant Antibodies (rAbs) Key Raw Materials Analysis
    • 7.1.1 Key Raw Materials
    • 7.1.2 Key Suppliers of Raw Materials
  • 7.2 Proportion of Manufacturing Cost Structure
  • 7.3 Manufacturing Process Analysis of Recombinant Antibodies (rAbs)
  • 7.4 Recombinant Antibodies (rAbs) Industrial Chain Analysis

8 Marketing Channel, Distributors and Customers

  • 8.1 Marketing Channel
  • 8.2 Recombinant Antibodies (rAbs) Distributors List
  • 8.3 Recombinant Antibodies (rAbs) Customers

9 Recombinant Antibodies (rAbs) Market Dynamics

  • 9.1 Recombinant Antibodies (rAbs) Industry Trends
  • 9.2 Recombinant Antibodies (rAbs) Growth Drivers
  • 9.3 Recombinant Antibodies (rAbs) Market Challenges
  • 9.4 Recombinant Antibodies (rAbs) Market Restraints

10 Global Market Forecast

  • 10.1 Recombinant Antibodies (rAbs) Market Estimates and Projections by Type
    • 10.1.1 Global Forecasted Sales of Recombinant Antibodies (rAbs) by Type (2022-2027)
    • 10.1.2 Global Forecasted Revenue of Recombinant Antibodies (rAbs) by Type (2022-2027)
  • 10.2 Recombinant Antibodies (rAbs) Market Estimates and Projections by Application
    • 10.2.1 Global Forecasted Sales of Recombinant Antibodies (rAbs) by Application (2022-2027)
    • 10.2.2 Global Forecasted Revenue of Recombinant Antibodies (rAbs) by Application (2022-2027)
  • 10.3 Recombinant Antibodies (rAbs) Market Estimates and Projections by Region
    • 10.3.1 Global Forecasted Sales of Recombinant Antibodies (rAbs) by Region (2022-2027)
    • 10.3.2 Global Forecasted Revenue of Recombinant Antibodies (rAbs) by Region (2022-2027)

11 Research Finding and Conclusion

    12 Methodology and Data Source

    • 12.1 Methodology/Research Approach
      • 12.1.1 Research Programs/Design
      • 12.1.2 Market Size Estimation
      • 12.1.3 Market Breakdown and Data Triangulation
    • 12.2 Data Source
      • 12.2.1 Secondary Sources
      • 12.2.2 Primary Sources
    • 12.3 Author List

    The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth.

    Segment by Type
    Rabbit
    Mouse
    Goat
    Others

    Segment by Application
    Hospitals & Diagnostic Laboratories
    Pharmaceutical & Biotechnology
    Research Institutes
    Others

    By Region
    North America
    United States
    Canada
    Europe
    Germany
    France
    U.K.
    Italy
    Russia
    Asia-Pacific
    China
    Japan
    South Korea
    India
    Australia
    Taiwan
    Indonesia
    Thailand
    Malaysia
    Latin America
    Mexico
    Brazil
    Argentina
    Middle East & Africa
    Turkey
    Saudi Arabia
    UAE

    By Company
    Abcam
    Abeomics
    Abnova Corporation
    Absolute Antibody
    Activity Signaling
    AIVD Biotech
    Bio X Cell
    BioLegend
    Bio-Rad
    Bon Opus Biosciences
    Creative Biolabs
    Creative Diagnostics
    Enzo Life Sciences, Inc.
    GRP GmbH
    HUABIO
    Miltenyi Biotec
    NSJ Bioreagents
    PROGEN
    RevMab Biosciences USA, Inc.
    Signalway Antibody LLC

    Buy now